Jilin Jian Yisheng Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Jilin Jian Yisheng Pharmaceutical has been growing earnings at an average annual rate of 5.1%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been declining at an average rate of 3.3% per year. Jilin Jian Yisheng Pharmaceutical's return on equity is 3.7%, and it has net margins of 10.8%.
Key information
5.1%
Earnings growth rate
5.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -3.3% |
| Return on equity | 3.7% |
| Net Margin | 10.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Jilin Jian Yisheng Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 803 | 87 | 492 | 18 |
| 31 Dec 23 | 854 | 95 | 508 | 19 |
| 30 Sep 23 | 858 | 81 | 513 | 19 |
| 30 Jun 23 | 871 | 87 | 507 | 20 |
| 31 Mar 23 | 855 | 85 | 495 | 20 |
| 01 Jan 23 | 830 | 83 | 491 | 19 |
| 30 Sep 22 | 827 | 91 | 479 | 21 |
| 30 Jun 22 | 851 | 98 | 487 | 19 |
| 31 Mar 22 | 874 | 95 | 510 | 20 |
| 01 Jan 22 | 878 | 96 | 506 | 21 |
| 30 Sep 21 | 902 | 91 | 519 | 16 |
| 30 Jun 21 | 901 | 89 | 528 | 18 |
| 31 Mar 21 | 871 | 86 | 513 | 16 |
| 31 Dec 20 | 843 | 80 | 498 | 16 |
| 30 Sep 20 | 881 | 75 | 522 | 19 |
| 30 Jun 20 | 904 | 69 | 547 | 20 |
| 31 Mar 20 | 968 | 81 | 577 | 20 |
| 31 Dec 19 | 1,013 | 77 | 607 | 19 |
| 30 Sep 19 | 971 | 71 | 608 | 19 |
| 30 Jun 19 | 957 | 70 | 592 | 18 |
| 31 Mar 19 | 963 | 66 | 594 | 20 |
| 31 Dec 18 | 975 | 69 | 601 | 20 |
| 30 Sep 18 | 1,037 | 69 | 612 | 21 |
| 30 Jun 18 | 1,066 | 70 | 609 | 29 |
| 31 Mar 18 | 1,065 | 62 | 627 | 23 |
| 31 Dec 17 | 1,034 | 60 | 607 | 20 |
| 30 Sep 17 | 1,007 | 26 | 602 | 15 |
| 30 Jun 17 | 984 | 18 | 621 | 0 |
| 31 Mar 17 | 958 | 17 | 609 | 0 |
| 31 Dec 16 | 939 | 13 | 602 | 0 |
| 30 Sep 16 | 812 | -29 | 604 | 0 |
| 30 Jun 16 | 811 | -19 | 596 | 0 |
| 31 Mar 16 | 846 | 11 | 553 | 0 |
| 31 Dec 15 | 820 | 11 | 537 | 0 |
| 30 Sep 15 | 950 | 100 | 498 | 0 |
| 30 Jun 15 | 903 | 103 | 463 | 0 |
| 31 Mar 15 | 797 | 93 | 433 | 0 |
| 31 Dec 14 | 788 | 96 | 426 | 0 |
| 30 Sep 14 | 693 | 83 | 439 | 0 |
| 30 Jun 14 | 672 | 88 | 421 | 0 |
| 31 Mar 14 | 674 | 89 | 419 | 0 |
| 31 Dec 13 | 644 | 87 | 400 | 0 |
| 30 Sep 13 | 633 | 98 | 365 | 0 |
| 30 Jun 13 | 632 | 99 | 365 | 0 |
Quality Earnings: 002566 has a large one-off gain of CN¥19.6M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 002566's current net profit margins (10.8%) are higher than last year (9.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002566's earnings have grown by 5.1% per year over the past 5 years.
Accelerating Growth: 002566's earnings growth over the past year (2.9%) is below its 5-year average (5.1% per year).
Earnings vs Industry: 002566 earnings growth over the past year (2.9%) did not outperform the Pharmaceuticals industry 8.5%.
Return on Equity
High ROE: 002566's Return on Equity (3.7%) is considered low.